Aripiprazole research over schizophrenia patients (both on first episode and recurrence) about its efficacy and influence on cognitive function

Aripiprazole research over schizophrenia patients (both on first episode and recurrence) about its efficacy and influence on cognitive function - Aripiprazole research over schizophrenia patients (both on first episode and recurrence) about its efficacy and influence on cognitive function

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002076

Enrollment

Registered

2009-06-14

Start date

2009-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

schizophrenia

Interventions

Monotherapy of aripiprazole: Estimate 8 weeks after the beginning, then follow up until 24 weeks (till 31/Mar/2012). About the dosage of aripiprazole, start at 6-12mg/day, then maintain at 6-30mg/da

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: schizophrenia patients diagnosed by DSM-4

Exclusion criteria

Exclusion criteria: patients using epinephrine patients with allergic reaction to aripiprazole before diabetic patients and patients who have history of suffering from diabetes patients with (or, with the possibility of) pregnancy patients taking other antipsychotics other patients not suitable for this study

Design outcomes

Primary

Measure	Time frame
apply neuropsychological tasks and evaluate the difference of the score	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026